Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.305 AUD | 0.00% | +5.17% | +41.86% |
24/04 | MedAdvisor Operating Revenue Rises 42% to AU$24.2 Million in March Quarter | MT |
23/04 | MedAdvisor's Gross Profit Climbs 48.5% in Fiscal Q3, Revenue Rises 42.4% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is highly valued given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.86% | 110M | - | ||
+4.63% | 32.55B | C | ||
+18.45% | 7.66B | C- | ||
+20.94% | 3.85B | B- | ||
-17.01% | 3.14B | C- | ||
-22.16% | 1.35B | B | ||
-31.01% | 1.18B | - | ||
+4.40% | 934M | C | ||
-34.81% | 911M | - | ||
-25.64% | 840M | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MDR Stock
- Ratings MedAdvisor Limited